*A previously treated patient was defined as a subject with a history of at least 150 exposure days to other FVIII products (adolescent/adult subjects) or 50 exposure days to other FVIII products (children below 6 years).†For adults and adolescents (children 12 years of age and above), the recommended starting dose is 50 IU of Esperoct^® per kg body weight every 4 days.‡Trial 3859 was a multi-centre, open-label, non-controlled trial evaluating the safety, efficacy and PK in prophylaxis and treatment of bleeds in previously treated adolescent and adult patients. This trial included 186 male subjects, 161 adults (18 to 65 years old) and 25 adolescents (12 to <18 years old); it consisted of a Main Phase and two Extension Phases. During the Main Phase, 175 subjects received the prophylaxis regimen which consisted of 50 IU every 3-4 days (Q3-4D), while 12 adults chose to be treated on-demand. All subjects received at least one dose of Esperoct^® and were evaluable for safety and efficacy.

Welcome to Esperoct®

Information for patients

Information for healthcare professionals

Welcome to
Esperoct^®